Monivent AB (XSAT:MONI) ROCE %: -235.77% (As of Mar. 2026)


XSAT:MONI Monivent AB XSAT:MONI
26 GF Score
Price kr0.41
GF Value kr0.05
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Monivent AB ROCE %?

Monivent AB XSAT:MONI +2.50% 26 ROCE % is -235.77% as of Mar. 2026. GuruFocus rates XSAT:MONI with a GF Score™ of 26/100 and a GF Value™ of kr0.05 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Monivent AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -235.77%.

Monivent AB  (XSAT:MONI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Monivent AB ROCE % Related Terms

Monivent AB ROCE % Historical Data

* Premium members only.

The historical data trend for Monivent AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monivent AB ROCE % Chart

Monivent AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -50.25 -70.70 -106.31 -200.68 -168.38

Monivent AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.43 -75.24 -102.30 -108.10 -235.77
XSAT:MONI
26GF Score
Monivent AB XSAT:MONI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monivent AB ROCE % Calculation

Monivent AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-8.541/( ( (12.06 - 7.692) + (12.78 - 7.003) )/ 2 )
=-8.541/( (4.368+5.777)/ 2 )
=-8.541/5.0725
=-168.38 %

Monivent AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-10.156/( ( (12.78 - 7.003) + (14.001 - 11.163) )/ 2 )
=-10.156/( ( 5.777 + 2.838 )/ 2 )
=-10.156/4.3075
=-235.77 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -235.77% mean?
Monivent AB (XSAT:MONI) has a ROCE % of -235.77% as of Mar. 2026.
Is Monivent AB's ROCE % too high?
Monivent AB's current ROCE % is -235.77%. Overall, Monivent AB has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monivent AB's ROCE % compare to ABT and SYK?
Monivent AB's ROCE % of -235.77% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monivent AB's current ROCE % is -235.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monivent AB stock overvalued right now?
Based on GuruFocus' analysis, Monivent AB (XSAT:MONI) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.41 — trading 720% above its estimated fair value. The current ROCE % is -235.77%. Monivent AB's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Monivent AB (XSAT:MONI), the current ROCE % is -235.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Monivent AB (XSAT:MONI) Overvalued in 2026?

Based on GuruFocus' analysis, Monivent AB stock appears to be overvalued. The current stock price of kr0.41 is trading 720% above its estimated GF Value™ of kr0.05. GuruFocus considers Monivent AB to be Significantly Overvalued.

Key valuation signals for XSAT:MONI:

  • ROCE %: -235.77%
  • GF Value™: kr0.05 vs. price of kr0.41 (720% above fair value)
  • GF Score™: 26/100 with 7 warning signs

No single metric tells the full story. See the XSAT:MONI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Monivent AB Business Description

Address Regnbagsgatan 8B, Gothenburg, SWE, SE-417 55
Monivent AB is a medtech company focused on improving the care given to newborn babies in need of respiratory support at birth. The company has developed a patented solution that provides continuous feedback on the volumes of air given to the newborn during manual ventilation. The airflow is measured directly in the face mask and feedback on the ventilation parameters is displayed numerically and graphically in real-time on the external monitor. The company's product is Monivent Neo100.
26GF Score

Get the complete analysis for XSAT:MONI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.41
Price
kr0.05
GF Value